Immuneering Corporation Cost of Revenue
Immuneering Corporation (IMRX) reported Cost of Revenue of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-01.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2024-03-01
- Immuneering Corporation cost of revenue for the quarter ending 2023-12-31 was $0.00.
- Immuneering Corporation cost of revenue for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Immuneering Corporation cost of revenue for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Immuneering Corporation cost of revenue for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Immuneering Corporation cost of revenue for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Immuneering Corporation cost of revenue for fiscal 2022 was $158.12K, a 86.29% decline from fiscal 2021.
- Immuneering Corporation cost of revenue for fiscal 2021 was $1.15M, a 9.94% decline from fiscal 2020.
- Immuneering Corporation cost of revenue for fiscal 2020 was $1.28M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $0.00 derived: sum of 2 quarters · filed 2024-03-01 | $0.00 derived: sum of 3 quarters · filed 2024-03-01 | $0.00 10-K · filed 2024-03-01 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | $0.00 derived: sum of 3 quarters · filed 2024-03-01 | $19.34K derived: sum of 4 quarters · filed 2024-03-01 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2024-03-01 | $19.34K derived: sum of 3 quarters · filed 2024-03-01 | $67.28K derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $19.34K derived: sum of 2 quarters · filed 2024-03-01 | $67.28K derived: sum of 3 quarters · filed 2024-03-01 | $158.12K 10-K · filed 2024-03-01 |
| 2022-09-30 | $19.34K 10-Q · filed 2023-11-09 | $67.28K derived: sum of 2 quarters · filed 2023-11-09 | $158.12K 10-Q · filed 2023-11-09 | $364.34K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $47.93K 10-Q · filed 2023-08-03 | $138.78K 10-Q · filed 2023-08-03 | $345.00K derived: sum of 3 quarters · filed 2023-08-03 | $564.09K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $90.85K 10-Q · filed 2023-05-04 | $297.07K derived: sum of 2 quarters · filed 2023-05-04 | $516.15K derived: sum of 3 quarters · filed 2023-05-04 | $834.76K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $206.22K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $425.31K derived: sum of 2 quarters · filed 2023-03-06 | $743.91K derived: sum of 3 quarters · filed 2023-03-06 | $1.15M 10-K · filed 2023-03-06 |
| 2021-09-30 | $219.09K 10-Q · filed 2022-11-10 | $537.69K derived: sum of 2 quarters · filed 2022-11-10 | $946.85K 10-Q · filed 2022-11-10 | $1.42M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $318.60K 10-Q · filed 2022-08-10 | $727.76K 10-Q · filed 2022-08-10 | $1.20M derived: sum of 3 quarters · filed 2022-08-10 | $1.52M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $409.16K 10-Q · filed 2022-05-10 | $882.40K derived: sum of 2 quarters · filed 2022-05-10 | $1.20M derived: sum of 3 quarters · filed 2022-05-10 | $1.43M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $473.23K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $788.24K derived: sum of 2 quarters · filed 2022-03-10 | $1.03M derived: sum of 3 quarters · filed 2022-03-10 | $1.28M 10-K · filed 2022-03-10 |
| 2020-09-30 | $315.00K 10-Q · filed 2021-11-09 | $552.06K derived: sum of 2 quarters · filed 2021-11-09 | $807.09K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $237.06K 10-Q · filed 2021-09-09 | $492.09K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |